|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Improvement of prognosis for unresectable biliary tract cancer显示文摘AIM:To evaluate the chemotherapeutic outcomes and confirm the recent improvement of prognosis for unresectable biliary tract cancer.METHODS:A total of 186 consecutive patients with unresectable biliary tract cancer,who had been treated with chemotherapy between 2000 and 2009 at five institutions in Japan,were retrospectively analyzed.These patients were divided into three groups based on the year beginning chemotherapy:Group A(2000-2003),Group B(2004-2006),and Group C(2007-2009).The data were fixed at the end of December 2011.Overall survival and time-to-progression were analyzed and compared chronologically.RESULTS:No patient characteristics were significantly different among the three groups.The gallbladder was involved in about half of the patients in each group,and metastatic biliary tract cancer was present in three quarters of the enrollees.In Group A,5-fluorouracilbased chemotherapies were primarily selected as firstline chemotherapy,and only 24% were treated with second-line chemotherapy.In Group B,gemcitabine or S-1 monotherapy was mainly introduced as firstline chemotherapy,and 51% of the patients who were refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with monotherapy.In Group C,the combination therapy with gemcitabine and S-1 was mainly chosen as first-line chemotherapy,and 53% of the patients refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with combination therapy.The median timeto-progressions were 4.4 mo,3.5 mo and 5.9 mo in Groups A,B and C,respectively(4.4 mo vs 3.5 mo vs 5.9 mo,P < 0.01).The median overall survivals were 7.1,7.3,and 11.7 mo in Groups A,B and C(7.1 mo vs 7.3 mo vs 11.7 mo,P = 0.03).Induction rates of all three drugs(gemcitabine,platinum analogs,and fluoropyrimidine) in Groups A,B and C were 4%,2% and 27%(4% vs 2% vs 27%,P < 0.01).CONCLUSION:The prognosis of unresectable biliary tract cancer has improved recently.Using three effective drugs(gemcitabine,platinum analogs,and fluoropyrimidine) may improve the prognosis of this cancer. | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Naminatsu Takahara Naoki Sasahira Hirofumi Kogure Suguru Mizuno Hiroshi Yagioka Yukiko Ito Natsuyo Yamamoto Kenji Hirano Nobuo Toda Minoru Tada Masao Omata Kazuhiko Koike | 2013 | World Journal of Gastroenterology2013，19，1： | 8 |
| 2 | Clinical analysis of high serum IgE in autoimmune pancreatitis显示文摘AIM: To clarify the clinical significance of high serum IgE in autoimmune pancreatitis (AIP). METHODS: Forty-two AIP patients, whose IgE was measured before steroid treatment, were analyzed. To evaluate the relationship between IgE levels and the disease activity of AIP, we examined (1) Frequency of high IgE (> 170 IU/mL) and concomitant allergic dis-eases requiring treatment; (2) Correlations between IgG, IgG4, and IgE; (3) Relationship between the presence of extrapancreatic lesions and IgE; (4) Re-lationship between clinical relapse and IgE in patients treated with steroids, and (5) Transition of IgE before and after steroid treatment. RESULTS: IgE was elevated in 36/42 (86%) patients.Concomitant allergic disease was observed in seven patients (allergic rhinitis in three, bronchial asthma in three, and urticaria in one). There were no signifi-cant correlations between IgG, IgG4, and IgE (r = -0.168 for IgG, and r = -0.188 for IgG4). There was no significant difference in IgE in the patients with and without extrapancreatic lesions (526 ± 531 IU/mL vs 819 ± 768 IU/mL, P = 0.163), with and without clini-cal relapse (457 ± 346 IU/mL vs 784 ± 786 IU/mL, P = 0.374). There was no significant difference in IgE between before and after steroid treatment (723 ± 744 IU/mL vs 673 ± 660 IU/mL, P = 0.633). CONCLUSION: Although IgE does not necessarily reflect the disease activity, IgE might be useful for the diagnosis of AIP in an inactive stage. | Kenji Hirano Minoru Tada Hiroyuki Isayama Kazumichi Kawakubo Hiroshi Yagioka Takashi Sasaki Hirofumi Kogure Yousuke Nakai Naoki Sasahira Takeshi Tsujino Nobuo Toda Kazuhiko Koike | 2010 | World Journal of Gastroenterology2010，16，41： | 4 |
| 3 | Measurement of radial and axial forces of biliary self-expandable metallic stents显示文摘 | Hiroyuki Isayama Yousuke Nakai Yoshihide Toyokawa Osamu Togawa Chimyon Gon Yukiko Ito Yoko Yashima Hiroshi Yagioka Hirofumi Kogure Takashi Sasaki Toshihiko Arizumi Saburo Matsubara Natsuyo Yamamoto Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Mi | 2009 | Gastrointestinal Endoscopy2009，，1： | 2 |
| 4 | Diagnostic utility of biopsy specimens for autoimmune pancreatitis显示文摘 | Kenji Hirano Noriyoshi Fukushima Minoru Tada Hiroyuki Isayama Suguru Mizuno Keisuke Yamamoto Yoko Yashima Hiroshi Yagioka Takashi Sasaki Hirofumi Kogure Yousuke Nakai Naoki Sasahira Takeshi Tsujino Takao Kawabe Masashi Fukayama Masao Omata | 2009 | Journal of Gastroenterology2009，，7： | 1 |
| 5 | Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy显示文摘 | Yousuke Nakai Hiroyuki Isayama Takashi Sasaki Naoki Sasahira Takeshi Tsujino Hirofumi Kogure Hiroshi Yagioka Yoko Yashima Osama Togawa Toshihiko Arizumi Saburo Matsubara Kenji Hirano Minoru Tada Masao Omata Kazuhiko Koike | 2010 | Critical Reviews in Oncology and Hematology2010，，： | 1 |
| 6 | Bezafibrate for the treatment of primary sclerosing cholangitis显示文摘 | Suguru Mizuno Kenji Hirano Minoru Tada Keisuke Yamamoto Yoko Yashima Hiroshi Yagioka Kazumichi Kawakubo Yukiko Ito Hirofumi Kogure Takashi Sasaki Toshihiko Arizumi Osamu Togawa Saburo Matsubara Yousuke Nakai Naoki Sasahira Takeshi Tsujino Hiroyuki Isayama | 2010 | Journal of Gastroenterology2010，，7： | 1 |
| 7 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine显示文摘 | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Suguru Mizuno Keisuke Yamamoto Hiroshi Yagioka Yoko Yashima Kazumichi Kawakubo Hirofumi Kogure Osamu Togawa Saburo Matsubara Yukiko Ito Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Minoru Tada Masao | 2012 | Investigational New Drugs2012，，2： | 1 |
| 8 | Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis显示文摘 | Kenji Hirano Minoru Tada Hiroyuki Isayama Keisuke Yamamoto Suguru Mizuno Hiroshi Yagioka Yoko Yashima Takashi Sasaki Hirofumi Kogure Osamu Togawa Toshihiko Arizumi Saburo Matsubara Yousuke Nakai Naoki Sasahira Takeshi Tsujino Takao Kawabe Masao Omata | 2010 | Gastrointestinal Endoscopy2010，，1： | 1 |
| 9 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine显示文摘 | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Suguru Mizuno Keisuke Yamamoto Hiroshi Yagioka Yoko Yashima Kazumichi Kawakubo Hirofumi Kogure Osamu Togawa Saburo Matsubara Yukiko Ito Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Minoru Tada Masao | 2012 | Investigational New Drugs2012，，2： | 1 |
| 10 | Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer显示文摘 | Yousuke Nakai Hiroyuki Isayama Hirofumi Kogure Tsuyoshi Hamada Osamu Togawa Yukiko Ito Saburo Matsubara Toshihiko Arizumi Hiroshi Yagioka Suguru Mizuno Takashi Sasaki Natsuyo Yamamoto Kenji Hirano Minoru Tada Kazuhiko Koike | 2014 | J Gastroenterol Hepatol2014，，9： | 1 |
| 11 | Results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial显示文摘 | Rie Uchino Hiroyuki Isayama Takeshi Tsujino Naoki Sasahira Yukiko Ito Saburo Matsubara Naminatsu Takahara Toshihiko Arizumi Nobuo Toda Dai Mohri Osamu Togawa Hiroshi Yagioka Yoshitsugu Yanagihara Katsuyoshi Nakajima Dai Akiyama Tsuyoshi Hamada Koji Miyaba | 2013 | Gastrointestinal Endoscopy2013，，6： | 1 |
| 12 | Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer显示文摘 | Tsuyoshi Hamada Hiroyuki Isayama Yousuke Nakai Osamu Togawa Hirofumi Kogure Kazumichi Kawakubo Takeshi Tsujino Naoki Sasahira Kenji Hirano Natsuyo Yamamoto Toshihiko Arizumi Yukiko Ito Saburo Matsubara Takashi Sasaki Hiroshi Yagioka Yoko Yashima Dai Mohri | 2011 | Gastrointestinal Endoscopy2011，，3： | 1 |
| 13 | Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer显示文摘AIM:To evaluate the differences in the treatment outcomes between the unresectable and recurrent biliary tract cancer patients who received chemotherapy.METHODS:Patients who were treated with gemcitabine and S-1 combination therapy in the previous prospective studies were divided into groups of unresectable and recurrent cases.The tumor response,time-toprogression,overall survival,toxicity,and dose intensity were compared between these two groups.RESULTS:Response rate of the recurrent group was higher than that of the unresectable group(40.0%vs25.5%;P=0.34).Median time-to-progression of the recurrent and unresectable groups were 8.7 mo(95%CI),1.2 mo,not reached)and 5.7 mo(95%CI:4.0-7.0 mo),respectively(P=0.14).Median overall survival of the recurrent and the unresectable groups were 16.1 mo(95%CI:2.0 mo-not reached)and 9.6 mo(95%CI:7.1-11.7 mo),respectively(P=0.10).Dose intensities were significantly lower in the recurrent groups(gemcitabine:recurrent group 83.5%vs unresectable group 96.8%;P<0.01,S-1:Recurrent group 75.9%vs unresectable group 91.8%;P<0.01).Neutropenia occurred more frequently in recurrent group(recurrent group 90%vs unresectable group 55%;P=0.04).CONCLUSION:Not only the efficacy but also the toxicity and dose intensity were significantly different between unresectable and recurrent biliary tract cancer. | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Yukiko Ito Ichiro Yasuda Nobuo Toda Hiroshi Yagioka Saburo Matsubara Keiji Hanada Hiroyuki Maguchi Hideki Kamada Osamu Hasebe Tsuyoshi Mukai Yoshihiro Okabe Iruru Maetani Kazuhiko Koike | 2014 | World Journal of Gastroenterology2014，20，48： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员